BC Week In Review | Nov 24, 2014
Clinical News

MDCO-216: Phase I data

A placebo-controlled Phase I trial in 24 healthy volunteers and 24 patients with documented coronary artery disease (CAD) showed that single doses of 5-40 mg/kg MDCO-216 were well tolerated with no serious adverse events or...
BC Week In Review | Sep 5, 2011
Clinical News

RVX-208: Additional Phase II data

Additional data from the double-blind, U.S. Phase II ASSERT trial in 299 patients showed that 100-300 mg daily RVX-208 enhanced biomarkers of reverse cholesterol transport and a reduction in inflammatory biomarkers. Specifically, RVX-208 plus standard...
Items per page:
1 - 2 of 2